

Technology Advisory Interests Register

**Topic: Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma
[ID2725]**

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	TAC C Committee Member	Direct- financial	Michael has participated in an advisory panel for Pfizer (comparator company) in an unrelated disease area (prostate cancer).	13/12/2024 09/04/2025	It was agreed that Michaels's declaration would not prevent him from participating in discussions on this appraisal.
Kate Ren	TAC C Committee Member	Direct- financial	Kate has provided statistical methodology consultancy service to a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	13/12/2024 09/04/2025	It was agreed that Kate's declaration would not prevent her from participating in discussions on this appraisal.
Satish Venkateshan	TAC C Committee Member	Direct- financial	Regeneron has cemiplimab, a PD1 inhibitor licensed for a variety of indications and being developed for several other tumour types/malignancies. Satish works for Regeneron, pharmaceuticals/biotech company. He also owns shares in the company and have stock options.	18/12/2024	It was agreed that Satish's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Elizabeth Thurgar	TAC C Committee Member	Direct- financial	Elizabeth has worked with Pfizer in an unrelated disease area (NSCLC).	09/04/2025	It was agreed that Elizabeth's declaration would not prevent her from participating in discussions on this appraisal.
Dr David Pinato	Clinical Expert	Direct- financial and Professional	<p>David has engagement with Astra Zeneca relating to:</p> <ul style="list-style-type: none"> • receipt of speaker fees for events (symposia, lectures) related to management of liver cancer on a national and international basis • receipt of professional fees for participation to advisory boards relating to liver cancer and anti-cancer immunotherapy • These activities included David advising the company on the topic of the submission 	08/01/2025	It was agreed that David's declaration would not prevent him from providing expert advice to the committee.
Professor Tim Meyer	Clinical Expert	Direct- financial	Tim has been on advisory boards for Roche, Astra Zeneca, Guerbet, Ipsen, GreyWolf, Signant Health and Parabilis Medicines. He has received Institution research grants from MSD, Bayer and Boston Scientific	18/12/2024	It was agreed that Tim's declaration would not prevent him from providing expert advice to the committee.

DRAFT